Down 85%! Why Affymax, Inc. (AFFY) is Getting Crushed This Morning

Look out below Affymax, Inc. (NASDAQ:AFFY) investors. The company pulled its only drug off of the market, and shares of the company are indicated to fall around 85% this morning according to Yahoo! Finance.

In collaboration with Japanese pharmaceutical company Takeda, Affymax developed a drug called Omontys for dialysis patients with anemia, or low red blood cell levels. The drug’s benefits over existing treatments had some investors optimistic about its commercial potential. But much of that hope was lost on Saturday morning, when the partners announced a voluntary recall of the drug after a small percentage of patients experienced serious initial side effects, leading to a handful of patient deaths.

Affymax, Inc. (NASDAQ:AFFY)The market Omontys was looking to penetrate is huge, and dominated by industry giants Amgen, Inc. (NASDAQ:AMGN) and Johnson & Johnson (NYSE:JNJ). Amgen’s Epogen and Aranesp combined for more than $2.7 billion in sales in 2012. J&J’s Procrit, which is the same underlying drug as Epogen, brought in nearly $1.5 billion. And while the overall market for the branded anemia drugs has been shrinking, Omontys only has to be taken once a month versus multiple times per week for Procrit and and Epogen. That advantage could have seen the drug take plenty of market share over the long term, despite rising generic competition.

I won’t mince words, this is a crushing blow for Affymax. With its sole drug pulled off of the market for safety concerns, the long term viability of the company is in serious question. But if the company can determine the reasons for the reactions and address them in an acceptable way, this may not be the end for Omontys and Affymax. The adverse events appeared to only happen during the initial dose, which suggests that long term use is safe. However, its clear from premarket activity that investors are expecting the worst.

Management is providing an update to discuss the news at 8:30 a.m. EST. You can access the webcast at Amgen’s investor relations page.

Is bigger really better?
Today’s Affymax news highlights a key consideration for investors when investing in small biotech stocks with highly concentrated risks. However, even the strongest, most diversified health care stocks have their detractors.

The article Down 85%! Why Affymax is Getting Crushed This Morning originally appeared on Fool.com and is written by Brenton Flynn.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!